Virtual clinical trial simulations for a novel KRAS G12C inhibitor (ASP2453) in non-small cell lung cancer

KRAS is a small GTPase family protein that relays extracellular growth signals to cell nucleus. KRAS mutations lead to constitutive proliferation signaling and are prevalent across human cancers. ASP2453 is a novel, highly potent, and selective inhibitor of KRAS . Although preclinical data suggested...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CPT: pharmacometrics and systems pharmacology 2021-08, Vol.10 (8), p.864-877
Hauptverfasser:	Sayama, Hiroyuki, Marcantonio, Diana, Nagashima, Takeyuki, Shimazaki, Masashi, Minematsu, Tsuyoshi, Apgar, Joshua F, Burke, John M, Wille, Lucia, Nagasaka, Yasuhisa, Kirouac, Daniel C
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Computer Simulation Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mice Mitogen-Activated Protein Kinase 1 - metabolism Mitogen-Activated Protein Kinase 3 - metabolism Models, Biological Mutation Network Pharmacology Phosphorylation Proto-Oncogene Proteins p21(ras) - genetics Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!